Current status and future development of antitubercular chemotherapy

Bibliography

• ENARSON DA, CHRETIEN J: Epidemiology of respiratory infectious diseases. Cup: Opin. Pam. Med. (1999) 5(3):128–135.
   PubMedGoogle Scholar
• MURRAY CJ, SALOMON JA: Modelling the impact of global tuberculosis control strategies. Proc. Nati Acad. Sci. USA (1998) 95(23):13881–13886.
   PubMed Web of Science ®Google Scholar
• ESPINAL MA, KIM SJ, SUAREZ PG et al.: Standard short-course chemotherapy for drug-resistant tuberculosis. JAMA (2000) 283(19):2537–2545.
   PubMed Web of Science ®Google Scholar
• TURETT GS, TELZAK EE, TORIAN LV et al.: Improved outcomes for patients with multidrug-resistant tuberculosis. Clio. Infect. Dis. (1995) 21(5):1238–1244.
   PubMed Web of Science ®Google Scholar
• BLANCHARD J: Molecular mechanisms of drug resistance in Mycobacterium tuberculosis Ann. Rev Biochem. (1996) 65:215–239.
   PubMed Web of Science ®Google Scholar
• ••A thorough review of antitubercularmechanisms of resistance.
   Google Scholar
• CHOPRA I, BRENNAN P: Molecular action of anti-mycobacterial agents. Tuber. Lung Dis. (1997) 78(2):89–98.
   PubMedGoogle Scholar
• RAMASWAMY S, MUSSER JM: Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis. 1998 update. Tuber. Lung Dis. (1998) 79(1):3–29. A thorough review of antitubercular mechanisms of resistance.
   Google Scholar
• KREMER L, BAULARD A, BESRA GS: Genetics of mycolic acid biosynthesis. In: Molecular Genetics of Mycobacteria. Hatfull GF, Jacobs WR (Eds.), ASM Press, Washington DC, USA (2000):173–190.
   Google Scholar
• ••A thorough review on mycolic acidbiosynthesis.
   Google Scholar
• ZHANG Y, HEYM B, ALLEN B, YOUNG D, COLE S: The catalase-peroxidase gene and isoniazid resistance in Mycobacterium tuberculosis. Nature (1992) 358(6387):591–593.
   PubMed Web of Science ®Google Scholar
• ••Evidence that KatG activates INH.
   Google Scholar
• JOHNSSON K, SCHULTZ, P: Mechanism studies of the oxidation of isoniazid by the catalase-perioxidase from Mycobacterium tuberculosis J. Am. Chem. Soc. (1994) 116:7425–7426.
   Web of Science ®Google Scholar
• BANERJEE A, DUBNAU E, QUEMARD A et al.: inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis Science (1994) 263 (5144) : 227–230.
   Google Scholar
• ••First report of the molecular target of INH.
   Google Scholar
• DESSEN A, QUEMARD A, BLANCHARD JS, JACOBS WR JR, SACCHETTINI JC: Crystal structure and function of the isoniazid target of Mycobacterium tuberculosis Science (1995) 267(5204):1638–1641.
   Google Scholar
• ••Important information relating to thecrystal structure of the target of INH.
   Google Scholar
• QUEMARD A, SACCHETTINI JC, DESSEN A et al.: Enzymatic characterization of the target for isoniazid in Mycobacterium tuberculosis Biochemistry (1995) 34(26):8235–8241.
   Google Scholar
• VILCHEZE C, MORBID ONI HR, WEISBROD TR et al.: Inactivation of the inhA-encoded fatty acid synthase II (FASH) enoyl-acyl carrier protein reductase induces accumulation of the FASI end products and cell lysis of Mycobacterium smegmatis. Bacteria (2000) 182(14):4059–4067.
   PubMed Web of Science ®Google Scholar
• LARSEN MH, VILCHEZE C, KREMER L et al.: Overexpression of inhA, but not kasA, confers resistance to isoniazid and ethionamide in Mycobacterium smegmatis, M bovis BCG, and M tuberculosis Ma. Microbia (In press).
   Google Scholar
• ••InhA as the target of INH.
   Google Scholar
• ROZWARSKI DA, GRANT GA, BARTON DH, JACOBS WR, SACCHETTINI JC: Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis Science (1998) 279(5347):98–102.
   Google Scholar
• RISKA PF, JACOBS WR, ALLAND D: Molecular determinants of drug resistance in tuberculosis. Int. J. Tuberc. Lung Dis. (2000) 4(2):54–S10.
   Google Scholar
• MIESEL L, WEISBROD TR, MARCINKEVICIENE JA, BITTMAN R, JACOBS WR JR: NADH dehydrogenase defects confer isoniazid resistance and conditional lethality in Mycobacterium smegmatis. J. Bacteria (1998) 180(9):2459–2467.
   PubMed Web of Science ®Google Scholar
• LEE AS, TEO AS, WONG SY: Novel mutations in ndh in isoniazid-resistant Mycobacterium tuberculosis isolates. Antimicrob. Agents Chemother. (2001) 45(7):2157–2159.
   PubMed Web of Science ®Google Scholar
• PAYTON M, AUTY R, DELGODA R, EVERETT M, SIM E: Cloning and characterization of arylamine N-acetyltransferase genes from Mycobacterium smegmatis and Mycobacterium tuberculosis: increased expression results in isoniazid resistance. J. Bacteria (1999) 181(4):1343–1347.
   PubMed Web of Science ®Google Scholar
• UPTON AM, MUSHTAQ A, VICTOR TC et al.: Arylamine N-acetyltransferase of Mycobacterium tuberculosis is a polymorphic enzyme and a site of isoniazid metabolism. Ma Microbia (2001) 42(2):309–317.
   PubMed Web of Science ®Google Scholar
• WILSON TM, COLLINS DM: alipC, a gene involved in isoniazid resistance of the Mycobacterium tuberculosis complex. Moi Microbia (1996) 19(5):1025–1034.
   PubMed Web of Science ®Google Scholar
• DUBNAU E, SOARES S, HUANG TJ, JACOBS WR JR: Overproduction of mycobacterial ribosomal protein S13 induces catalase/peroxidase activity and hypersensitivity to isoniazid in Mycobacterium smegmatis. Gene (1996) 170(1):17–22.
   PubMed Web of Science ®Google Scholar
• CHEN P, BISHAI WR Novel selection for isoniazid (INH) resistance genes supports a role for NAD±-binding proteins in mycobacterial INH resistance. Infect. Immun. (1998) 66(11):5099–5106.
   PubMed Web of Science ®Google Scholar
• SLAYDEN RA, BARRY CE: The genetics and biochemistry of isoniazid resistance in Mycobacterium tuberculosis. Microbes Infect. (2000) 2(6):659–669.
   PubMed Web of Science ®Google Scholar
• ••A thorough review of resistance mechanismsto INH.
   Google Scholar
• KUSHNER S, DALALIAN H, SANJURO JL et al.: Experimental chemotherapy of tuberculosis. II. The synthesis of pyrazinamides and related compounds. J. Am. Chem. Soc. (1952) 74:3617–3621.
   Web of Science ®Google Scholar
• GORDIN F, CHAISSON RE, MATTS JP et al.: Rifampin and pyrazinamide versus isoniazid for prevention of tuberculosis in HIV-infected persons. An international randomized trial. JA/VIA (2000) 283(11):1445–1449.
   Google Scholar
• CYNAMON MH, SPEIRS RJ, WELCH JT: In vitro antimycobacterial activity of 5-chloropyrazinamide. Antimicrob. Agents Chemother. (1998) 42(2):462–463
   PubMed Web of Science ®Google Scholar
• SCORPIO A, ZHANG Y: Mutations in pncA, a gene encoding pyrazinamidase/ nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat. Med. (1996) 2(6):662–667.
   PubMed Web of Science ®Google Scholar
• ••Evidence that PncA activates PZA.
   Google Scholar
• ZIMHONY 0, COX JS, WELCH JT, VILCHEZE C, JACOBS WR, Jr: Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FAST) of Mycobacterium tuberculosis Nat. Med. (2000) 6(9):1043–1047.
   Web of Science ®Google Scholar
• ••Presents FAS-I as the target for PZA.
   Google Scholar
• BOSHOFF HI, MIZRAHI V, BARRY CE, III. Effects of pyrazinamide on fatty acid synthesis by whole mycobacterial cells and purified fatty acid synthase 1.1 Bacteria (2002) 184(8):2167–2172.
   Google Scholar
• MASUR H: Recommendations on prophylaxis and therapy for disseminated Mycobacterium avium complex disease in patients infected with the human immunodeficiency virus. Public Health Service Task Force on Prophylaxis and Therapy for Mycobacterium avium Complex. N Eng]. J. Med. (1993) 329(12):898–904.
   Google Scholar
• TAKAYAMA K, ARMSTRONG EL, KUNIGI KA, KILBURN JO: Inhibition by ethambutol of mycolic acid transfer into the cell wall of Mycobacterium smegmatis. Antimicrob. Agents Chemother. (1979) 16(2):240–242.
   PubMed Web of Science ®Google Scholar
• KILBURN JO, TAKAYAMA K: Effects of ethambutol on accumulation and secretion of trehalose mycolates and free mycolic acid in Mycobacterium smegmatis. Antimicrob. Agents Chemother. (1981) 20(3):401–404.
   PubMed Web of Science ®Google Scholar
• TAKAYAMA K, KILBURN JO: Inhibition of synthesis of arabinogalactan by ethambutol in Mycobacterium smegmatis Antimicrob. Agents Chemother. (1989) 33(9):1493–14999.
   PubMed Web of Science ®Google Scholar
• BELANGER AE, BESRA GS, FORD ME et al.: The embAB genes of Mycobacterium avium encode an arabinosyl transferase involved in cell wall arabinan biosynthesis that is the target for the antimycobacterial drug ethambutol. Proc. Nati Acad. Sci USA (1996) 93(21):11919–11924.
   PubMed Web of Science ®Google Scholar
• ••The identification of the mode of action ofEMB.
   Google Scholar
• TELENTI A, PHILIPP WJ, SREEVATSANet al. The emb operon, a gene cluster ofMycobacterium tuberculosis involved in resistance to ethambutol. Nat. Med. (1997) 3(5):567–570.
   Google Scholar
• ESCUYER VE, LETY MA, TORRELLESJB et al.: The role of the embA and embB gene products in the biosynthesis of the terminal hexaarabinofuranosyl motif of Mycobacterium smegmatis arabinogalactan. Biol. Chem. (2001) 276(52):48854–48862.
   Web of Science ®Google Scholar
• •Analysis of Emb mutants in relation to arabinogalactan biosynthesis.
   Google Scholar
• SREEVATSAN S, STOCKBAUER KE, PAN X et al.: (1997) Ethambutol resistance in Mycobacterium tuberculosic critical role of embB mutations. Antimicrob. Agents Chemother: 41(8):1677–1681.
   Google Scholar
• WOODLEY CL, KILBURN JO, DAVID HL, SILCOX VA: Susceptibility of mycobacteria to rifampin. Antimicrob. Agents Chemother: (1972) 2 (4) :245–249.
   PubMed Web of Science ®Google Scholar
• DAVIDSON PT, LE HQ: Drug treatment of tuberculosis-1992. Drugs (1992) 43(5):651–673.
   PubMed Web of Science ®Google Scholar
• LEVIN ME, HATFULL GF: Mycobacterium smegmatis RNA polymerase: DNA supercoiling, action of rifampicin and mechanism of rifampicin resistance. Ma Microbia (1993) 8(2):277–285.
   PubMed Web of Science ®Google Scholar
• TELENTI A, IMBODEN P, MARCHESI F et al.: Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet (1993) 341(8846):647–650.
   PubMed Web of Science ®Google Scholar
• DAVIES J, WRIGHT GD: Bacterial resistance to aminoglycoside antibiotics. Trends MicrobioL (1997) 5(6):234–240.
   PubMed Web of Science ®Google Scholar
• HONORE N, COLE ST: Streptomycin resistance in mycobacteria. Antimicrob. Agents Chemother: (1994) 38(2):238–242.
   PubMed Web of Science ®Google Scholar
• DOUGLASS J, STEYN LM: A ribosomal gene mutation in streptomycin-resistant Mycobacterium tuberculosis isolates. J. Infect. Dis. (1993) 167(6):1505–1506.
   PubMed Web of Science ®Google Scholar
• FINKEN M, KIRSCHNER P, MEIER A, WREDE A, BOTTGER EC: Molecular basis of streptomycin resistance in Mycobacterium tuberculosis: alterations of the ribosomal protein S12 gene and point mutations within a functional 16S ribosomal RNA pseudoknot. Ma. Microbia (1993) 9(6):1239–1246.
   PubMed Web of Science ®Google Scholar
• MEIER A, KIRSCHNER P, BANGE FC, VOGEL U, BOTTGER EC: Genetic alterations in streptomycin-resistant Mycobacterium tuberculosis: mapping of mutations conferring resistance. Antimicrob. Agents Chemother: (1994) 38(2):228–233.
   PubMed Web of Science ®Google Scholar
• MORRIS S, BAI GH, SUFFYSP, PORTILLO-GOMEZ L, FAIRCHOK M, ROUSE D: Molecular mechanisms of multiple drug resistance in clinical isolates of Mycobacterium tuberculosis. J. Infect. Dis. (1995) 171(4):954–960.
   PubMed Web of Science ®Google Scholar
• BAULARD AR, BETTS JC, ENGOHANG-NDONG J et al.: Activation of the pro-drug ethionamide is regulated in mycobacteria. Biol. Chem. (2000) 275(36):28326–28331.
   Web of Science ®Google Scholar
• ••Description of the mechanism of activationof the pro-drug ETH.
   Google Scholar
• DeBARBER AE, MDLULI K, BEKKER LG, BARRY CE, 3rd: Ethionamide activation and sensitivity in multi-drug resistant Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. USA (2000) 97(17):9677–9682.
   PubMed Web of Science ®Google Scholar
• ••Description of the mechanism of activationof the pro-drug ETH.
   Google Scholar
• VANNELLI TA, DYKMAN A, ORITZ De MONTELLANO PR: The antituberculosis drug ethionamide is activated by a flavoprotein monooxygenase. Biol. Chem. (2002) 277(15):12824–12829.
   Web of Science ®Google Scholar
• GAY JD, DEYOUNG DR, ROBERTS GD: ha vitro activities of norfloxacin and ciprofloxacin against Mycobacterium tuberculosis, M. avium complex, M chelonei, M fortuitum, and M kansasii Antimicrob. Agents Chemother. (1984) 26(1):94–96.
   Google Scholar
• LEYSEN DC, HAEMERS A, PATTYN SR: Mycobacteria and the new quinolones. Antimicrob. Agents Chemother (1989) 33(1):1–5.
   PubMed Web of Science ®Google Scholar
• BRYSKIER A, LOWTHER J: Fluoroquinolones and tuberculosis. Expert. Opin. Investig. Drugs (2002) 11(2):233–258.
   PubMed Web of Science ®Google Scholar
• FRIEDEN TR, SHERMAN LF, MAW KL et al.: A multi-institutional outbreak of highly drug-resistant tuberculosis: epidemiology and clinical outcomes. JAMA (1996) 276(15):1229–1235.
   PubMed Web of Science ®Google Scholar
• TAKIFF HE, SALAZAR L, GUERRERO C et al.: Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob. Agents Chemother (1994) 38(4):773–780.
   PubMed Web of Science ®Google Scholar
• SULLIVAN EA, KREISWIRTH BN, PALUMBO L et al: Emergence of fluoroquinolone-resistant tuberculosis in New York City. Lancet (1995) 345(8958):1148–1150.
   PubMed Web of Science ®Google Scholar
• JI B, LOUNIS N, MASLO C, TRUFFOT-PERNOT C, BONNAFOUS P, GROSSET J: ha vitro and in vivo activities of mwdfloxacin and clinafloxacin against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. (1998) 42(8):2066–2069.
   PubMed Web of Science ®Google Scholar
• MIYAZAKI E, MIYAZAKI M, CHEN JM, CHAISSON RE, BISHAI WR: Mwdfloxacin (BAY12-8039), a new 8-methoxyquinolone is active in a mouse model of tuberculosis. Antimicrob. Agents Chemother. (1999) 43(1):85–89.
   PubMed Web of Science ®Google Scholar
• WINDER FG: Mode of action of the antimycobacterial agents and associated aspects of the molecular biology of mycobacteria. In: The biology of the mycobacteria (Volume D. Ratledge C, Stanford J (eds), Academic Press, London, UK (1982):354–441.
   Google Scholar
• YAWALKAR SJ, VISCHER W: Lamprene (clofazimine) in leprosy. Lep. Rev (1979) 50(2):135–144.
   PubMed Web of Science ®Google Scholar
• REDDY VM, O'SULLIVAN JF, GANGADHARAM PRJ: Antimycobacterial activities of riminophenazines. I Antimibrob. Chemother. (1999) 43(5):615–623.
   PubMed Web of Science ®Google Scholar
• BARRY VC, BELTON JG, CONALTY ML et al.: A new series of phenazines (rimino-compounds) with high antituberculosis activity. Nature (1957) 179(4568):1013–1015.
   PubMed Web of Science ®Google Scholar
• MORRISON NE, MARLEY GM: The mode of action of clofazimine DNA binding studies. hat. J. Lepr. Other Mycobact. Dis. (1976) 44(1-2):133–134.
   PubMedGoogle Scholar
• DAVID HL, TAKAYAMA K, GOLDMAN DS: Susceptibility of mycobacterial D-alanyl-D-alanyl synthetase to D-cycloserine. Am. Rev Respir. Dis. (1969) 100(4):579–581.
   PubMed Web of Science ®Google Scholar
• CACERES NE, HARRIS NB, WELLEHAN JF, FENG Z, KAPUR V, BARLETTA RG: Overexpression of the D-alanine racemase gene confers resistance to D-cycloserine in Mycobacterium smegmatis .1. Bacteria (1997) 179(16):5046–5055.
   Google Scholar
• LEHMANN J: Para-aminosalicylic acid intreatment of tuberculosis. Lancet (1946) 1:15–16.
   PubMed Web of Science ®Google Scholar
• PELOQUIN CA, BERNING SE, HUITT GA et al.: Once-daily and twice-daily dosing of p-aminosalicylic acid granules. Am. J. Respir. Crit. Care Med. (1999) 159(3):932–934.
   PubMed Web of Science ®Google Scholar
• BROWN KA, RATLEDGE C: The effect of p-aminosalicyclic acid on iron transport and assimilation in mycobacteria. Biochim. Biophys. Acta (1975) 385(2):207–220.
   PubMed Web of Science ®Google Scholar
• HEIFETS, LB, LINDHOLM-LEVY PJ, FLORY M: Thiacetazone: in vitro activity against Mycobacterium avium and M tuberculosis Tubercle (1990) 71(4):287–291.
   Google Scholar
• HERR EB, Jr, REDSTONE MO: Chemical and physical characterization of capreomycin. Ann. NY Acad. Sci. (1966) 135(2):940–946.
   PubMedGoogle Scholar
• SINGLA R, GUPTA S, GUPTA R, ARORA VK: Efficacy and safety of sparfloxacin in combination with kanamycin and ethionamide in multidrug-resistant pulmonary tuberculosis patients: preliminary results. Ira] j Tuberc. Lung Dis. (2001) 5(6):559–563.
   PubMed Web of Science ®Google Scholar
• ALANGADEN GJ, KREISWIRTH BN, AOUAD A et al: Mechanism of resistance to amikacin and kanamycin in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. (1998) 42(5):1295–1297.
   PubMed Web of Science ®Google Scholar
• TSUKAMURA M, MIZUNO S: Cross-resistant relationships among the aminoglycoside antibiotics in Mycobacterium tuberculosis. .1. Gen Microbia (1975) 88(2):269–274.
   Google Scholar
• HEGDE SS, JAVID-MAJD F, BLANCHARD JS: Overexpression and mechanistic analysis of chromosomally encoded aminoglycoside 2'-N-acetyltransferase (AAC(2')-Ic) from Mycobacterium tuberculosis. I Biol. Chem. 276(49):45876–45881.
   Google Scholar
• REDDY VM, NADADHUR G, DANELUZZI D, O'SULLIVAN JF, GANGADHARAM PRJ: Antituberculosis activities of clofazimine and its new analogs B4154 and B4157. Antimicrobial. Agents Chemother. (1996) 40(3):633–636.
   PubMed Web of Science ®Google Scholar
• TUCKER IA, ALLWINE DA, GREGA KC et al.: Piperazinyl oxazolidinone antibacterial agents containing a pyridine, diazene, or triazene heteroaromatic ring. J. Med. Chem. (1998) 41(19):3727–3735.
   PubMed Web of Science ®Google Scholar
• BARBACHYN MR, HUTCHINSON DK, BRICKNER SJ et al.: Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity. J. Med. Chem. (1996) 39(3):680–685.
   PubMed Web of Science ®Google Scholar
• CYNAMON MH, KLEMENS SP, SHARPE CA, CHASE S: Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model. Antimicrob. Agents Chemother. (1999) 43(5):1189–1191.
   PubMed Web of Science ®Google Scholar
• YAMAMOTO T, AMITANI R, SUZUKI K, TANAKA E, MURAYAMA T, KUZE F: In vitro bactericidal and in vivo therapeutic activities of a new rifamycin derivative, KW-1648, against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. (1996) 40(2):426–428.
   PubMed Web of Science ®Google Scholar
• POTKAR C, GOGTAY N, GOKHALE P et al.: Phase I pharmacokinetic study of a new 3-azinomethyl-rifamycin (rifametane) as compared to rifampicin. Chemotherapy (1999) 45(3):147–153.
   PubMed Web of Science ®Google Scholar
• WAYNE LG, SRAMEK HA: Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis. Antimicrob. Agents Chemother (1994) 38(9):2054–2058.
   PubMed Web of Science ®Google Scholar
• ASHTEKAR DR, COSTA-PERIRA R, NAGRAJAN K, VISHVANATHAN N, BHATT AD, RITTEL W: ha vitro and in vivo activities of the nitroimidazole CGI 17341 against Mycobacterium tuberculosis. Antimicrob. Agents Chemother: (1993) 37(2):183–186.
   PubMed Web of Science ®Google Scholar
• STOVER CK, WARRENER P, VanDEVANTER DR et al.: A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature (2000) 405(6789):962–966.
   PubMed Web of Science ®Google Scholar
• ••Description of a new potent moleculeagainst TB.
   Google Scholar
• WINDER FG, COLLINS PB, WHELAN D: Effects of ethionamide and isoxyl on mycofic acid synthesis in Mycobacterium tuberculosisBCG. Gen. Microbiol. (1971) 66(3):379–380.
   PubMedGoogle Scholar
• PHETSUKSIRI B, BAULARD AR, COOPER AM et al.: Antimycobacterial activities of isoxyl and new derivatives through the inhibition of mycofic acid synthesis. Antimicrob. Agents Chemother: (1999) 43(5):1042–1051.
   PubMed Web of Science ®Google Scholar
• •Interesting report examining a series of old antitubercular agents.
   Google Scholar
• OISHI H, NOTO T, SASAKI H et al: Thiolactomycin, a new antibiotic. I. Taxonomy of the producing organism, fermentation and biological properties. Antibiot. (Tokyo) (1982) 35(4):391–395.
   PubMed Web of Science ®Google Scholar
• SASAKI H, OISHI H, HAYASHI T, MATSUURA I, ANDO K, SAWADA M: Thiolactomycin, a new antibiotic. II. Structure elucidation. Antibiot (Tokyo) (1982) 35(4):396–400.
   PubMed Web of Science ®Google Scholar
• NOTO T, MIYAKAWA S, OISHI H, ENDO H, OKAZAKI H: Thiolactomycin, a new antibiotic. III. ha vitro antibacterial activity. Antibiot. (Tokyo) (1982) 35(4):401–410.
   PubMed Web of Science ®Google Scholar
• SLAYDEN RA, LEE RE, ARMOUR JW et al.: Antimycobacterial action of thiolactomycin: an inhibitor of fatty acid and mycofic acid synthesis. Antimicrob. Agents Chemother. (1996) 40(12):2813–2819.
   PubMed Web of Science ®Google Scholar
• ••Description of antimycobacterial activity ofthiolactomycin.
   Google Scholar
• MIYAKAWA S, SUZUKI K, NOTO T, HARADA Y, OKAZAKI H: Thiolactomycin, a new antibiotic. IV. Biological properties and chemotherapeutic activity in mice. Antibiot. (Tokyo) (1982) 35(4):411–419.
   PubMed Web of Science ®Google Scholar
• KREMER L, DOUGLAS JD, BAULARD AR et al.: Thiolactomycin and related analogues as novel anti-mycobacterial agents targeting KasA and KasB condensing enzymes in Mycobacterium tuberculosis. Biol. Chem. (2000) 275(22):16857–16864.
   Web of Science ®Google Scholar
• ••The potential of thiolactomycin as a novelTB agent.
   Google Scholar
• SCHAEFFER ML, AGNIHOTRI G, VOLKER C, KALLENDER H, BRENNAN PJ, LONSDALE JT: Purification and biochemical characterization of the Mycobacterium tuberculosis beta-ketoacyl-acyl carrier protein synthases, KasA and KasB. Biol. Chem. (2001) 276(50):47029–47037.
   Web of Science ®Google Scholar
• KREMER L, DOVER LG, CARRERE S. et al.: Mycolic acid biosynthesis and enzymatic characterization of the 13-ketoacyl-ACP synthase A-condensing enzyme from Mycobacterium tuberculosis. Biochem. (2002) 364\(Pt2): 423–430.
   Google Scholar
• LIN YM, FLAVIN MT, CASSIDY CS, MAR A, CHEN FC: Biflavonoids as novel antituberculosis agents. Bioorg. Med. Chem. Lett. (2001) 11:2101–2104.
   PubMed Web of Science ®Google Scholar
• DEIDDA D, LAMPIS G, FIORAVANTI R et al.: Bactericidal activities of the pyrrole derivative BM212 against multi-drug resistant and intramacrophagic Mycobacterium tuberculosis strains. Antimicrob. Agents Chemother. (1998) 42(11):3035–3037.
   PubMed Web of Science ®Google Scholar
• PARRISH NM, HOUSTON T, JONES PB, TOWNSEND C, DICK JD: ha vitro activity of a novel antimycobacterial compound, N octanesulfonylacetamide, and its effects on lipid and mycolic acid synthesis. Antimicrob. Agents Chemother. (2001) 45(4):1143–1150.
   PubMed Web of Science ®Google Scholar
• OLEKSIJEW A, MEULBROEK J, EWING P et al.: In vivo efficacy of ABT-255 against drug-sensitive and -resistant Mycobacterium tuberculosis strains. Antimicrob. Agents Chemother. (1998) 42(10):2674–2677.
   PubMed Web of Science ®Google Scholar
• TRAMONTANA JM, UTAIPAT T, MOLLOY A et al.: Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis. Ma Med. (1995) 1(4):384–397.
   Google Scholar
• WALLIS RS, NSUBUGA P, WHALEN C et al: Pentoxifylfine therapy in human immunodeficiency virus-seropositive persons with tuberculosis: a randomized, controlledtrial. Infect. Dis. (1996) 174(4):727–733.
   Google Scholar
• CONDOS R, ROM WN, SCHLUGER NW: Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol. Lancet (1997) 349(9064):1513–1515.
   PubMed Web of Science ®Google Scholar
• BRENNAN PJ, NIKAIDO H: The envelope of mycobacteria. Ann. Rev Biochem. (1995) 64:29–63.
   PubMed Web of Science ®Google Scholar
• ••Retrospective description of themycobacterial cell wall.
   Google Scholar
• DENG L, MIKUSOVA K, ROBUCK KG, SCHERMAN M, BRENNAN PJ, McNEIL MR: Recognition of multiple effects of ethambutol on metabolism of mycobacterial cell envelope. Antimicrob. Agents Chemother: (1995) 39(3):694–701.
   PubMed Web of Science ®Google Scholar
• MIKUSOVA K, MIKUS M, BESRA GS, HANCOCK I, BRENNAN PJ: Biosynthesis of the linkage region of the mycobacterial cell wand, Biol. Chem. (1996) 271(13):7820–7828.
   Google Scholar
• ••Biochemical studies detailing the synthesisof the key linkage unit involved in cell wall biosynthesis.
   Google Scholar
• COLE ST, BROSCH R, PARKHILL J et al: Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature (1998) 393(6685):537–544.
   PubMed Web of Science ®Google Scholar
• ••Complete description of the M tuberculosisgenome sequence.
   Google Scholar
• MAY, MILLS JA, BELISLE JT et al: Determination of the pathway for rhamnose biosynthesis in mycobacteria: cloning, sequencing and expression of the Mycobacterium tuberculosis gene encoding alpha-D-glucose-l-phosphate thymidylyltransferase. Microbiology (1997) 143(Pt 3):937–945.
   PubMedGoogle Scholar
• STERN, RJ, LEE TY, LEE TJ et al: Conversion of dTDP-4-keto-6-deoxyglucose to free dTDP-4-keto-rhamnose by the rmIC gene products of Escherichia coil and Mycobacterium tuberculosis. Microbiology (1999) 145(3):663–671.
   PubMedGoogle Scholar
• MAY, STERN RJ, SCHERMAN MS et al: Drug targeting Mycobacterium tuberculosis cell wall synthesis: genetics of dTDP-rhamnose synthetic enzymes and development of a microtiter plate-based screen for inhibitors of conversion of dTDP-glucose to dTDP-rhamnose. Antimicrob. Agents Chemother: (2001) 45(5):1407–1416.
   PubMed Web of Science ®Google Scholar
• BESRA GS, BRENNAN PJ: The mycobacterial cell wall: biosynthesis of arabinogalactan and lipoarabinomannan. Biochem. Soc. Trans (1997) 25(3):845–850.
   PubMed Web of Science ®Google Scholar
• KREMER L, DOVER LG, MOREHOUSE C et al: Galactan biosynthesis in Mycobacterium tuberculosic identification of a bifunctional UDP-Galactofuranosyltransferase. J. Biol. Chem. (2001) 276(28): 26430–26440.
   PubMed Web of Science ®Google Scholar
• ••The identification of how the galactansegment of arabinogalactan is synthesised.
   Google Scholar
• VVESTON A, STERN RJ, LEE RE et al: Biosynthetic origin of mycobacterial cell wall galactofuranosyl residues. Tuber. Lung Dis. (1997) 78(2):123–131.
   PubMedGoogle Scholar
• SANDERS DA, STAINES AG, McMAHON SA, McNEIL MR, WHITFIELD C, NAISMITH JH: UDP-galactopyranose mutase has a novel structure and mechanism. Nat. Struct. Biol. (2001) 8(10):858–863.
   PubMedGoogle Scholar
• PAN F, JACKSON M, MAY, McNEIL M: Cell wall core galactofuran synthesis is essential for growth of mycobacteria. Bacteria. (2001) 183(13):3991–3998.
   PubMed Web of Science ®Google Scholar
• •An important piece of research examining the essentiality issue of cell wall galactan biosynthesis.
   Google Scholar
• WOLUCKA BA, MCNEIL MR, DE HOFFMANN E, CHOJNACKI T, BRENNAN PJ: Recognition of the lipid intermediate for arabinogalactan/ arabinomannan biosynthesis and its relation to the mode of action of ethambutol on mycobacteria. Biol. Chem. (1994) 269(37):23328–23335.
   Web of Science ®Google Scholar
• SCHERMAN MS, KALBE- BOURNONVILLE L, BUSH D, XIN Y, DENG L, McNEIL MR: Polyprenylphosphate-pentoses in mycobacteria are synthesized from 5-phosphoribose pyrophosphate. I Biol. Chem. (1996) 271(47):29652–29658.
   Web of Science ®Google Scholar
• BLOCH K: Control mechanisms for fatty acid synthesis in Mycobacterium smegmatis Adv Enzymol Relat. Areas Mol Biol. (1977) 45:1–84.
   PubMedGoogle Scholar
• WOOD WI, PETERSEN DO, BLOCH K: Mycobacterium smegmatis fatty acid synthetase, a mechanism based on steady state rates and product distributions. J. Biol. Chem. (1977) 252(16):5745–5749.
   PubMed Web of Science ®Google Scholar
• CAMPBELL JVV, CRONAN JE: Bacterial fatty acid biosynthesis: Targets for antibacterial drug discovery. Ann. Rev Microbiol (2001) 55:305–332.
   PubMed Web of Science ®Google Scholar
• CHOI KH, KREMER L, BESRA GS, ROCK CO: Identification and substrate specificity of beta-ketoacyl (acyl carrier protein) synthase III (mtFabH) from Mycobacterium tuberculosis I Biol. Chem. (2000) 275(36):28201–28207.
   Google Scholar
• ••Key report on the initiation step involved inFAS-II biosynthesis.
   Google Scholar
• SCARSDALE JN, KAZANINA G, HEX, REYNOLDS KA, WRIGHT HT: Crystal structure of the Mycobacterium tuberculosis beta-ketoacyl-acyl carrier protein synthase 111.j Biol. Chem. (2001) 276(23):20516–20522.
   Google Scholar
• MDLULI K, SLAYDEN RA, ZHU Y et al: Inhibition of a Mycobacterium tuberculosis beta-ketoacyl ACP synthase by isoniazid. Science (1998) 280(5369):1607–1610.
   PubMed Web of Science ®Google Scholar
• BELISLE JT, VISSA VD, SIEVERT T, TAKAYAMA K, BRENNAN PJ, BESRA GS: Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis. Science (1997) 276(5317):1420–1422.
   PubMed Web of Science ®Google Scholar
• ••Conclusive evidence of a mycolyltransferaseenzyme involved in cell wall mycolylation.
   Google Scholar
• JACKSON M, RAYNAUD C, LANEELLE MA et al.: Inactivation of the antigen 85C gene profoundly affects the mycolate content and alters the permeability of the Mycobacterium tuberculosis cell envelope. Mol Micro. (1999) 31(5):1573–1587.
   PubMed Web of Science ®Google Scholar
• KREMER L, MAUGHAN W, WILSON RA, DOVER LG, BESRA GS: The M tuberculosis antigen 85 complex and mycolyltransferase activity. Lett. Appl. Microbial. (2002) 34(4):233–237.
   PubMed Web of Science ®Google Scholar
• BESRA GS, SIEVERT T, LEE RE, SLAYDEN RA, BRENNAN PJ, TAKAYAMA K: Identification of the apparent carrier in mycolic acid synthesis. Proc. Nati Acad. Sci. USA (1994) 91(26):12735–12739.
   PubMed Web of Science ®Google Scholar
• SCHULBACH MC, BRENNAN PJ, CRICK DC: Identification of a short (C15) chain Z-isoprenyl diphosphate synthase and a homologous long (C50) chain isoprenyl diphosphate synthase in Mycobacterium tuberculosis .1. Biol. Chem. (2000) 275(30):22876–22881.
   Google Scholar
• MCKINNEY JD, HONER ZU, BENTRUP K, MUNOZ-ELIAS EJ et al: Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature (2000) 406(6797):735–738.
   PubMed Web of Science ®Google Scholar
• GLICKMAN MS, COX JS, JACOBS WR JR: A novel mycolic acid cyclopropane synthase is required for cording, persistence and virulence of Mycobacterium tuberculosis. Cell(2000) 5(4):717–727.
   Web of Science ®Google Scholar
• COX JS, CHEN B, MCNEIL M, JACOBS WR: Complex lipid determines tissue-specific replication of Mycobacterium tuberculosis in mice. Nature (1999) 402 (6757) :79–83.
   PubMed Web of Science ®Google Scholar
• ••An interesting report demonstrating theimportance of cell wall lipids.
   Google Scholar
• CAMACHO LR, CONSTANT P, RAYNAUD C et al.: Analysis of the phthiocerol dimycocerosate locus of Mycobacterium tuberculosis Evidence that this lipid is involved in the cell wall permeability barrier. I. Biol. Chem. (2001) 276(23):19845–19854.
   Web of Science ®Google Scholar
• MINNIKIN DE, KREMER L, DOVER LG, BESRA GS: The methyl-branched fortifications of Mycobacterium tuberculosis. Chem. Biol (2002) 9(5):545–553.
   PubMed Web of Science ®Google Scholar
• HONDALUS MK, BARDAROV S, RUSSELL R, CHAN J, JACOBS WR JR, BLOOM BR: Attenuation of and protection induced by a leucine auxotroph of Mycobacterium tuberculosis. Infect. Immun. (2000) 68(5):2888–2898.
   PubMed Web of Science ®Google Scholar
• GORDHAN BG, SMITH DA, ALDERTON H, McADAM RA, BANCROFT GJ, MIZRAHI V: Construction and phenotypic characterization of an auxotrophic mutant of Mycobacterium tuberculosis defective in L-arginine biosynthesis. Infect. Immun. (2002) 70(6):3080–3084.
   PubMed Web of Science ®Google Scholar
• BARDAROV S, KRIAKOV J, CARRIERE C et al.: Conditionally replicating mycobacteriophages: a system for transposon delivery to Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. USA (1998) 94(20):10961–10966.
   Web of Science ®Google Scholar
• BESRA GS, KREMER L: Re-emergence of tuberculosis: strategies and treatment. Expert Opin. Investig. Drugs (2002) 11(2):153–157.
   PubMed Web of Science ®Google Scholar